ASH 2022 Conference Coverage
ASH 2022 on the Phase Ib/II Study of Polatuzumab Vedotin + Obinutuzumab & Lenalidomide in R/R Follicular Lymphoma: Final Analysis and PFS Update
By
ASH 2022 Conference Coverage
FEATURING
Catherine Diefenbach
By
ASH 2022 Conference Coverage
FEATURING
Catherine Diefenbach
Comments 0
Login to view comments.
Click here to Login
